<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851643</url>
  </required_header>
  <id_info>
    <org_study_id>V502-002</org_study_id>
    <secondary_id>2009_552</secondary_id>
    <nct_id>NCT00851643</nct_id>
  </id_info>
  <brief_title>Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)</brief_title>
  <official_title>A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL™ Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX™ (IMX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and tolerability of octavalent Human Papillomavirus (HPV)
      L1 Virus-Like Particle (VLP) vaccine formulated with amorphous aluminum hydroxysulfate (AAHS)
      and ISCOMATRIX™ (IMX). Reviews of safety and tolerability will be used to select the dose(s)
      of IMX for further studies of the octavalent HPV L1 VLP vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was performed in 2 staggered phases, Phase A and Phase B. In Phase A, participants
      were randomized to qHPV, Octavalent HPV with 15 mcg IMX/AAHS, or Octavalent HPV with 30 mcg
      IMX/AAHS. After the safety for Phase A was reviewed, Phase B was initiated. In Phase B,
      participants were randomized to qHPV, Octavalent HPV with 60 mcg IMX/AAHS or Octavalent HPV
      with 120 mcg IMX/AAHS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase A</measure>
    <time_frame>4 weeks postdose 3 (Phase A)</time_frame>
    <description>The quadrivalent HPV (GARDASIL™) vaccine has types 6, 11, 16, 18, and the octavalent HPV has types 6, 11, 16, 18, 31, 45, 52, and 58. Serum antibody titres to the HPV type were obtained using a competitive Luminex immunoassay (cLIA) after vaccination with GARDASIL™ or the octavalent HPV vaccine. GMTs were calculated and are reported as the antibody concentration in milli-Merck Units per milliliter (mMU/mL) of neutralizing monoclonal antibody equivalent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase B</measure>
    <time_frame>4 weeks postdose 3 (Phase B)</time_frame>
    <description>The quadrivalent HPV (GARDASIL™) vaccine has types 6, 11, 16, 18, and the octavalent HPV has types 6, 11, 16, 18, 31, 45, 52, and 58. Serum antibody titres to the HPV type were obtained using cLIA after vaccination with GARDASIL™ or the octavalent HPV vaccine. GMTs were calculated and are reported as the antibody concentration in milli-Merck Units per milliliter (mMU/mL) of neutralizing monoclonal antibody equivalent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Seroconverted to Each of the HPV Types Contained in the Vaccine During Phase A</measure>
    <time_frame>4 weeks postdose 3 (Phase A)</time_frame>
    <description>A vaccinated participant was considered seropositive for a given HPV type if her serum antibody titer by cLIA for the HPV type was greater than the serostatus cutoff. The serostatus cutoffs for HPV Types 6, 11, 16, 18, 31, 45, 52, and 58 were 20, 20, 20, 20, 16, 16, 20, and 16 mMU/mL, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Seroconverted to Each of the HPV Types Contained in the Vaccine During Phase B</measure>
    <time_frame>4 weeks postdose 3 (Phase B)</time_frame>
    <description>A vaccinated participant was considered seropositive for a given HPV type if her serum antibody titer by cLIA for the HPV type was greater than the serostatus cutoff. The serostatus cutoffs for HPV Types 6, 11, 16, 18, 31, 45, 52, and 58 were 20, 20, 20, 20, 16, 16, 20, and 16 mMU/mL, respectively.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Human Papilloma Virus</condition>
  <condition>Cervical Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <condition>Genital Warts</condition>
  <arm_group>
    <arm_group_label>qHPV (GARDASIL™) - Phase A Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quadrivalent Human Papillomavirus (qHPV) (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 15 mcg ISCOMATRIX™ (IMX) / Aluminum Hydroxyphosphate Sulfate (AAHS) and Octavalent HPV with 30 mcg IMX / AAHS during Phase A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octavalent HPV with 15 mcg IMX / AAHS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg AAHS and 15 mcg IMX.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octavalent HPV with 30 mcg IMX / AAHS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>qHPV (GARDASIL™) - Phase B Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 60 mcg IMX / AAHS and Octavalent HPV with 120 mcg IMX / AAHS during Phase B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octavalent HPV with 60 mcg IMX / AAHS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octavalent HPV with 120 mcg IMX / AAHS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octavalent HPV with 15 mcg IMX / AAHS</intervention_name>
    <description>0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6</description>
    <arm_group_label>Octavalent HPV with 15 mcg IMX / AAHS</arm_group_label>
    <other_name>V502</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octavalent HPV with 30 mcg IMX / AAHS</intervention_name>
    <description>0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6</description>
    <arm_group_label>Octavalent HPV with 30 mcg IMX / AAHS</arm_group_label>
    <other_name>V502</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octavalent HPV with 60 mcg IMX / AAHS</intervention_name>
    <description>0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6</description>
    <arm_group_label>Octavalent HPV with 60 mcg IMX / AAHS</arm_group_label>
    <other_name>V502</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octavalent HPV with 120 mcg IMX / AAHS</intervention_name>
    <description>0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6</description>
    <arm_group_label>Octavalent HPV with 120 mcg IMX / AAHS</arm_group_label>
    <other_name>V502</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)</intervention_name>
    <description>0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6</description>
    <arm_group_label>qHPV (GARDASIL™) - Phase A Control</arm_group_label>
    <arm_group_label>qHPV (GARDASIL™) - Phase B Control</arm_group_label>
    <other_name>V502-002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is in good physical health

          -  Participant has had a lifetime history of 0 to 4 sexual partners

          -  Females between 18-to-24 years

        Exclusion Criteria:

          -  Participant has a history of abnormal Pap test

          -  Participant has a history of positive test for HPV

          -  Participant has a history of recent or ongoing alcohol or drug abuse

          -  Participant is immunocompromised or has an autoimmune condition

          -  Participant has received immunosuppressive therapy within a year of screening

          -  Participant has previously received an HPV vaccine

          -  Participant is pregnant

          -  Participant has a history of external genital/vaginal warts

          -  Participant is currently enrolled in a clinical trial

          -  Participant has a history of a severe allergic reaction that required medical
             attention
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <results_first_submitted>February 10, 2011</results_first_submitted>
  <results_first_submitted_qc>May 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2011</results_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>158 participants were enrolled. Of the enrolled 158 participants, 8 were screening failures. 150 participants were randomized to the base study (up to 12 months), conducted in 2 phases, Phase A and Phase B. Some participants continued in a voluntary, long-term extension of the study (up to 36 months).</recruitment_details>
      <pre_assignment_details>In Phase A, participants were randomized to quadrivalent Human Papillomavirus (qHPV), Octavalent HPV with 15 mcg ISCOMATRIX™ (IMX) / Aluminum Hydroxyphosphate Sulfate (AAHS), or Octavalent HPV with 30 mcg IMX/AAHS. In Phase B, participants were randomized to qHPV, Octavalent HPV with 60 mcg IMX/AAHS or Octavalent HPV with 120 mcg IMX/AAHS.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>qHPV (GARDASIL™) - Phase A Control</title>
          <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)- controls from Phase A. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="P2">
          <title>Octavalent HPV With 15 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 15 mcg ISCOMATRIX™ (IMX). A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="P3">
          <title>Octavalent HPV With 30 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="P4">
          <title>qHPV (GARDASIL™) - Phase B Control</title>
          <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)- controls from Phase B. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="P5">
          <title>Octavalent HPV With 60 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="P6">
          <title>Octavalent HPV With 120 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study (Up to 12 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study (Up to 36 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>qHPV (GARDASIL™) - Phase A Control</title>
          <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)- Controls from Phase A. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="B2">
          <title>Octavalent HPV With 15 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate(AAHS) and 15 mcg ISCOMATRIX™ (IMX). A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="B3">
          <title>Octavalent HPV With 30 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="B4">
          <title>qHPV (GARDASIL™) - Phase B Control</title>
          <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)- Controls from Phase B. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="B5">
          <title>Octavalent HPV With 60 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="B6">
          <title>Octavalent HPV With 120 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="30"/>
            <count group_id="B6" value="30"/>
            <count group_id="B7" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.3" spread="1.6"/>
                    <measurement group_id="B2" value="20.8" spread="1.8"/>
                    <measurement group_id="B3" value="20.2" spread="1.5"/>
                    <measurement group_id="B4" value="19.9" spread="1.6"/>
                    <measurement group_id="B5" value="20.5" spread="1.8"/>
                    <measurement group_id="B6" value="20.8" spread="2.0"/>
                    <measurement group_id="B7" value="20.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase A</title>
        <description>The quadrivalent HPV (GARDASIL™) vaccine has types 6, 11, 16, 18, and the octavalent HPV has types 6, 11, 16, 18, 31, 45, 52, and 58. Serum antibody titres to the HPV type were obtained using a competitive Luminex immunoassay (cLIA) after vaccination with GARDASIL™ or the octavalent HPV vaccine. GMTs were calculated and are reported as the antibody concentration in milli-Merck Units per milliliter (mMU/mL) of neutralizing monoclonal antibody equivalent.</description>
        <time_frame>4 weeks postdose 3 (Phase A)</time_frame>
        <population>Per Protocol Immunogenicity (PPI) population: participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and polymerase chain reaction (PCR)-negative Day 1 through Month 7 for the relevant HPV type(s), had a valid Month 7 serology result collected in the appropriate day range.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV (GARDASIL™) - Phase A Control</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) for Phase A</description>
          </group>
          <group group_id="O2">
            <title>Octavalent HPV With 15 mcg IMX / AAHS</title>
            <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 15 mcg ISCOMATRIX™(IMX)</description>
          </group>
          <group group_id="O3">
            <title>Octavalent HPV With 30 mcg IMX / AAHS</title>
            <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 30 mcg ISCOMATRIX™ (IMX)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase A</title>
          <description>The quadrivalent HPV (GARDASIL™) vaccine has types 6, 11, 16, 18, and the octavalent HPV has types 6, 11, 16, 18, 31, 45, 52, and 58. Serum antibody titres to the HPV type were obtained using a competitive Luminex immunoassay (cLIA) after vaccination with GARDASIL™ or the octavalent HPV vaccine. GMTs were calculated and are reported as the antibody concentration in milli-Merck Units per milliliter (mMU/mL) of neutralizing monoclonal antibody equivalent.</description>
          <population>Per Protocol Immunogenicity (PPI) population: participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and polymerase chain reaction (PCR)-negative Day 1 through Month 7 for the relevant HPV type(s), had a valid Month 7 serology result collected in the appropriate day range.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6 (N=11, N=21, N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1273.3" lower_limit="704.9" upper_limit="2300.1"/>
                    <measurement group_id="O2" value="2203.0" lower_limit="1658.9" upper_limit="2925.6"/>
                    <measurement group_id="O3" value="4784.7" lower_limit="3741.5" upper_limit="6118.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11 (N=11, N=21, N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1991.6" lower_limit="1096.3" upper_limit="3618.2"/>
                    <measurement group_id="O2" value="2564.3" lower_limit="1940.8" upper_limit="3388.3"/>
                    <measurement group_id="O3" value="3921.6" lower_limit="2964.4" upper_limit="5188.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16 (N=11, N=23, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2381.9" lower_limit="1558.5" upper_limit="3640.4"/>
                    <measurement group_id="O2" value="3961.8" lower_limit="2982.6" upper_limit="5262.4"/>
                    <measurement group_id="O3" value="7484.4" lower_limit="5493.9" upper_limit="10196.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18 (N=11, N=24, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="568.7" lower_limit="284.8" upper_limit="1135.7"/>
                    <measurement group_id="O2" value="1375.7" lower_limit="966.4" upper_limit="1958.2"/>
                    <measurement group_id="O3" value="2315.3" lower_limit="1453.4" upper_limit="3688.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31(N=11, N=24, N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" upper_limit="79.1">The lower bound of the 95% confidence interval is below the level of detectability (&lt;8).</measurement>
                    <measurement group_id="O2" value="2037.5" lower_limit="1502.4" upper_limit="2763.0"/>
                    <measurement group_id="O3" value="4782.3" lower_limit="3282.4" upper_limit="6967.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45 (N=11, N=26, N=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" upper_limit="52.7">The lower bound of the 95% confidence interval is below the level of detectability (&lt;4).</measurement>
                    <measurement group_id="O2" value="1042.8" lower_limit="760.8" upper_limit="1429.1"/>
                    <measurement group_id="O3" value="2116.5" lower_limit="1329.7" upper_limit="3368.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52 (N=9, N=23, N=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The lower and upper bounds of the 95% confidence interval are below the level of detectability (&lt;16 to &lt;16).</measurement>
                    <measurement group_id="O2" value="2531.1" lower_limit="1798.6" upper_limit="3561.9"/>
                    <measurement group_id="O3" value="4292.0" lower_limit="2997.7" upper_limit="6145.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58 (N=10, N=24, N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" upper_limit="86.1">The lower bound of the 95% confidence interval is below the level of detectability (&lt;6).</measurement>
                    <measurement group_id="O2" value="1759.2" lower_limit="1276.5" upper_limit="2424.4"/>
                    <measurement group_id="O3" value="3146.4" lower_limit="2335.4" upper_limit="4428.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase B</title>
        <description>The quadrivalent HPV (GARDASIL™) vaccine has types 6, 11, 16, 18, and the octavalent HPV has types 6, 11, 16, 18, 31, 45, 52, and 58. Serum antibody titres to the HPV type were obtained using cLIA after vaccination with GARDASIL™ or the octavalent HPV vaccine. GMTs were calculated and are reported as the antibody concentration in milli-Merck Units per milliliter (mMU/mL) of neutralizing monoclonal antibody equivalent.</description>
        <time_frame>4 weeks postdose 3 (Phase B)</time_frame>
        <population>PPI population: All participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR-negative Day 1 through Month 7
for the relevant HPV type(s), and had a valid Month 7 serology result collected in the appropriate day range.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV (GARDASIL™) - Phase B Control</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) for Phase B</description>
          </group>
          <group group_id="O2">
            <title>Octavalent HPV With 60 mcg IMX / AAHS</title>
            <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 60 mcg ISCOMATRIX™(IMX)</description>
          </group>
          <group group_id="O3">
            <title>Octavalent HPV With 120 mcg IMX / AAHS</title>
            <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 120 mcg ISCOMATRIX™ (IMX)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase B</title>
          <description>The quadrivalent HPV (GARDASIL™) vaccine has types 6, 11, 16, 18, and the octavalent HPV has types 6, 11, 16, 18, 31, 45, 52, and 58. Serum antibody titres to the HPV type were obtained using cLIA after vaccination with GARDASIL™ or the octavalent HPV vaccine. GMTs were calculated and are reported as the antibody concentration in milli-Merck Units per milliliter (mMU/mL) of neutralizing monoclonal antibody equivalent.</description>
          <population>PPI population: All participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR-negative Day 1 through Month 7
for the relevant HPV type(s), and had a valid Month 7 serology result collected in the appropriate day range.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV Type 6 (N=10, N=19, N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2350.9" lower_limit="1581.6" upper_limit="3494.2"/>
                    <measurement group_id="O2" value="6006.0" lower_limit="3991.6" upper_limit="9037.0"/>
                    <measurement group_id="O3" value="4484.8" lower_limit="2791.7" upper_limit="7204.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 11 (N=10, N=19, N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3762.2" lower_limit="2422.0" upper_limit="5844.1"/>
                    <measurement group_id="O2" value="6514.2" lower_limit="4520.8" upper_limit="9386.8"/>
                    <measurement group_id="O3" value="6609.3" lower_limit="5028.2" upper_limit="8687.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 16 (N=7, N=19, N=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2783.6" lower_limit="973.2" upper_limit="7961.8"/>
                    <measurement group_id="O2" value="12947.5" lower_limit="8856.5" upper_limit="18928.3"/>
                    <measurement group_id="O3" value="10105.9" lower_limit="6570.9" upper_limit="15542.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 18 (N=10, N=19, N=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="948.2" lower_limit="403.7" upper_limit="2227.1"/>
                    <measurement group_id="O2" value="5090.0" lower_limit="3467.5" upper_limit="7471.7"/>
                    <measurement group_id="O3" value="4070.9" lower_limit="3135.2" upper_limit="5285.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 31 (N=11, N=22, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" lower_limit="15.5" upper_limit="88.2"/>
                    <measurement group_id="O2" value="7779.0" lower_limit="4876.7" upper_limit="12408.5"/>
                    <measurement group_id="O3" value="5487.3" lower_limit="3683.0" upper_limit="8175.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 45 (N=11, N=20, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" upper_limit="10.9">The lower bound of the 95% confidence interval is below the level of detectability (&lt;4).</measurement>
                    <measurement group_id="O2" value="3974.8" lower_limit="2680.5" upper_limit="5894.0"/>
                    <measurement group_id="O3" value="4696.4" lower_limit="3499.6" upper_limit="6302.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 52 (N=10, N=20, N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The GMT is &lt;16, and the lower and upper bounds of the 95% confidence interval are below the level of detectability (&lt;16 to &lt;16).</measurement>
                    <measurement group_id="O2" value="5714.9" lower_limit="3962.4" upper_limit="8242.6"/>
                    <measurement group_id="O3" value="6624.6" lower_limit="4919.9" upper_limit="8919.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 58 (N=9, N=21, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" upper_limit="28.1">The lower bound of the 95% confidence interval is below the level of detectability (&lt;6).</measurement>
                    <measurement group_id="O2" value="4961.8" lower_limit="3170.1" upper_limit="7766.1"/>
                    <measurement group_id="O3" value="5191.2" lower_limit="4036.3" upper_limit="6676.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Seroconverted to Each of the HPV Types Contained in the Vaccine During Phase A</title>
        <description>A vaccinated participant was considered seropositive for a given HPV type if her serum antibody titer by cLIA for the HPV type was greater than the serostatus cutoff. The serostatus cutoffs for HPV Types 6, 11, 16, 18, 31, 45, 52, and 58 were 20, 20, 20, 20, 16, 16, 20, and 16 mMU/mL, respectively.</description>
        <time_frame>4 weeks postdose 3 (Phase A)</time_frame>
        <population>PPI population: All participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR-negative Day 1 through Month 7
for the relevant HPV type(s), and had a valid Month 7 serology result collected in the appropriate day range.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV (GARDASIL™) - Phase A Control</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) for Phase A</description>
          </group>
          <group group_id="O2">
            <title>Octavalent HPV With 15 mcg IMX / AAHS</title>
            <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 15 mcg ISCOMATRIX™(IMX)</description>
          </group>
          <group group_id="O3">
            <title>Octavalent HPV With 30 mcg IMX / AAHS</title>
            <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 30 mcg ISCOMATRIX™ (IMX)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Seroconverted to Each of the HPV Types Contained in the Vaccine During Phase A</title>
          <description>A vaccinated participant was considered seropositive for a given HPV type if her serum antibody titer by cLIA for the HPV type was greater than the serostatus cutoff. The serostatus cutoffs for HPV Types 6, 11, 16, 18, 31, 45, 52, and 58 were 20, 20, 20, 20, 16, 16, 20, and 16 mMU/mL, respectively.</description>
          <population>PPI population: All participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR-negative Day 1 through Month 7
for the relevant HPV type(s), and had a valid Month 7 serology result collected in the appropriate day range.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6 (N=11, N=21, N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11 (N=11, N=21, N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16 (N=11, N=23, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18 (N=11, N=24, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31 (N=11, N=24, N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45 (N=11, N=26, N=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52 (N=9, N=23, N=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58 (N=10, N=24, N=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Seroconverted to Each of the HPV Types Contained in the Vaccine During Phase B</title>
        <description>A vaccinated participant was considered seropositive for a given HPV type if her serum antibody titer by cLIA for the HPV type was greater than the serostatus cutoff. The serostatus cutoffs for HPV Types 6, 11, 16, 18, 31, 45, 52, and 58 were 20, 20, 20, 20, 16, 16, 20, and 16 mMU/mL, respectively.</description>
        <time_frame>4 weeks postdose 3 (Phase B)</time_frame>
        <population>PPI population: All participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR-negative Day 1 through Month 7
for the relevant HPV type(s), and had a valid Month 7 serology result collected in the appropriate day range.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV (GARDASIL™) - Phase B Control</title>
            <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) for Phase B</description>
          </group>
          <group group_id="O2">
            <title>Octavalent HPV With 60 mcg IMX / AAHS</title>
            <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 60 mcg ISCOMATRIX™(IMX)</description>
          </group>
          <group group_id="O3">
            <title>Octavalent HPV With 120 mcg IMX / AAHS</title>
            <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 120 mcg ISCOMATRIX™ (IMX)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Seroconverted to Each of the HPV Types Contained in the Vaccine During Phase B</title>
          <description>A vaccinated participant was considered seropositive for a given HPV type if her serum antibody titer by cLIA for the HPV type was greater than the serostatus cutoff. The serostatus cutoffs for HPV Types 6, 11, 16, 18, 31, 45, 52, and 58 were 20, 20, 20, 20, 16, 16, 20, and 16 mMU/mL, respectively.</description>
          <population>PPI population: All participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR-negative Day 1 through Month 7
for the relevant HPV type(s), and had a valid Month 7 serology result collected in the appropriate day range.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6 (N=10, N=19, N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11 (N=10, N=19, N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16 (N=7, N=19, N=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18 (N=10, N=19, N=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31 (N=11, N=22, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45 (N=11, N=20, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52 (N=10, N=20, N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58 (N=9, N=21, N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All injection site adverse events (AEs) for 5 days following vaccination, all non-injection site AEs for 14 calendar days following vaccination, and all laboratory AEs that occurred at any time during the study are included.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>qHPV (GARDASIL™) - Phase A and Phase B Controls</title>
          <description>Quadrivalent Human Papillomavirus (qHPV) (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) combined from Phase A and Phase B.</description>
        </group>
        <group group_id="E2">
          <title>Octavalent HPV With 15 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP vaccine adjuvanted with 281 mcg AAHS and 15 mcg IMX.</description>
        </group>
        <group group_id="E3">
          <title>Octavalent HPV With 30 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP vaccine adjuvanted with 281 mcg AAHS and 30 mcg IMX.</description>
        </group>
        <group group_id="E4">
          <title>Octavalent HPV With 60 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP vaccine adjuvanted with 281 mcg AAHS and 60 mcg IMX.</description>
        </group>
        <group group_id="E5">
          <title>Octavalent With 120 mcg IMX / AAHS</title>
          <description>Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP vaccine adjuvanted with 281 mcg AAHS and 120 mcg IMX.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E3" events="27" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E4" events="36" subjects_affected="21" subjects_at_risk="30"/>
                <counts group_id="E5" events="38" subjects_affected="20" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" events="10" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="62" subjects_affected="27" subjects_at_risk="30"/>
                <counts group_id="E2" events="94" subjects_affected="29" subjects_at_risk="30"/>
                <counts group_id="E3" events="101" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E4" events="95" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E5" events="89" subjects_affected="30" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E3" events="37" subjects_affected="22" subjects_at_risk="30"/>
                <counts group_id="E4" events="48" subjects_affected="24" subjects_at_risk="30"/>
                <counts group_id="E5" events="43" subjects_affected="22" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E5" events="15" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E3" events="29" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E4" events="30" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E5" events="46" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>As this study is part of a multicenter trial, the SPONSOR does not recommend separate publication of individual study site results due to scientific concerns. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President,Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

